- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-4 Registration of securities issued in business combination transactions
- 10.6 Exhibit 10.6
- 10.7 Exhibit 10.7
- 10.8 Exhibit 10.8
- 10.9 Exhibit 10.9
- 10.10 Exhibit 10.10
- 10.11 Exhibit 10.11
- 10.12 Exhibit 10.12
- 10.13 Exhibit 10.13
- 10.14 Exhibit 10.14
- 10.15 Exhibit 10.15
- 10.16 Exhibit 10.16
- 10.17 Exhibit 10.17
- 10.18 Exhibit 10.18
- 21.1 Exhibit 21.1
- 23.1 Exhibit 23.1
- 23.2 Exhibit 23.2
- 99.1 Exhibit 99.1
- 99.2 Exhibit 99.2
- 99.3 Exhibit 99.3
- 99.4 Exhibit 99.4
- 99.5 Exhibit 99.5
- 99.6 Exhibit 99.6
- 99.7 Exhibit 99.7
- Download Excel data file
- View Excel data file
- 3 Jan 24 EFFECT Notice of effectiveness
- 27 Dec 23 POS AM Prospectus update (post-effective amendment)
- 10 Jun 21 EFFECT Notice of effectiveness
- 9 Jun 21 424B3 Prospectus supplement
- 7 Jun 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 25 May 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 30 Apr 21 S-4/A Registration of securities issued in business combination transactions (amended)
-
22 Mar 21 S-4 Registration of securities issued in business combination transactions
- 7 Jun 21 Registration of securities issued in business combination transactions (amended)
- 25 May 21 Registration of securities issued in business combination transactions (amended)
- 30 Apr 21 Registration of securities issued in business combination transactions (amended)
- 22 Mar 21 Registration of securities issued in business combination transactions
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the inclusion in this Registration Statement on Form S-4 of Therapeutics Acquisition Corp. of our report dated March 15, 2021, with respect to our audits of the consolidated financial statements of POINT Biopharma, Inc. and Subsidiaries (the “Company”), which comprise the consolidated balance sheets as of December 31, 2020 and 2019, the related consolidated statements of operations, stockholders’ equity (deficit), and cash flows for the year ended December 31, 2020 and for the period from September 18, 2019 (inception) through December 31, 2019, and the related notes to the consolidated financial statements. We also consent to the reference of our firm under the heading “Experts” in this Registration Statement.
|
|
| /s/ Armanino LLP |
| San Jose, California |
|
|
March 22, 2021 |
|